Die ketogene Ernährung

Zusammenfassung

Es gibt bislang nur wenige Studien, die den Einfluss einer streng kohlenhydratreduzierten, sehr fettreichen, sog. „ketogenen“ Kost auf den Verlauf einer Krebserkrankung untersuchten. Da eine solche Kostform längerfristig Schwierigkeiten bei der Compliance zu Hause bereitet, ist ein supportiver Therapieansatz evtl. sinnvoller, weil er in Anlehnung an Fastenkuren mit den oxidativen Krebstherapien kombiniert werden kann.

Publication History

Article published online:
17 March 2021

• Literatur

• 1 Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70
• 2 Warburg O. Über den Stoffwechsel der Tumoren. Berlin: Springer; 1926
• 3 Lundholm K, Holm G, Schersten T. Insulin resistance in patients with cancer. Cancer Res 1978; 38: 4665-4670
• 4 Hansell DT, Davis JW, Shenkin A. et al. The oxidation of body fuel stores in cancer patients. Ann Surgery 1986; 204: 637-642
• 5 Kern L, Mittenbühler MJ, Vesting AJ. et al. Obesity-induced TNFalpha and IL-6 signaling: the missing link between obesity and inflammation-driven liver and colorectal cancers. Cancers (Basel) 2018; 11: E24
• 6 Coyle C, Cafferty FH, Vale C. et al. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol 2016; 27: 2184-2195
• 7 Martin-McGill KJ, Bresnahan R, Levy RG. et al. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev 2020; 6: CD001903 DOI: 10.1002/14651858.CD001903.pub5.
• 8 McDonald TJW, Cervenka MC. Ketogenic diet therapies for seizures and status epiliepticus. Semin Neurol 2020; 40: 719-729
• 9 Hallberg SJ, McKenzie AL, Williams PT. et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: An open-label, non-randomized, controlled study. Diabetes Ther 2018; 9: 583-612
• 10 Feng S, Wang H, Liu J. et al. Multi-dimensional roles of ketone bodies in cancer biology: Opportunities for cancer therapy. Pharmacol Res 2019; 150: 104500 DOI: 10.1016/j.phrs.2019.104500.
• 11 Otto C, Kaemmerer U, Illert B. et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer 2008; 8: 122 DOI: 10.1186/1471–2407–8-122.
• 12 Klement RJ, Champ CE, Otto C. et al. Anti-tumor effects of ketogenic diets in mice: A meta-analysis. PLoS One 2016; 11: e0155050 DOI: 10.1371/journal.pone.0155050.
• 13 Schmitt M, Pfetzer N, Schwab M. et al. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr Metab 2011; 8: 54 DOI: 10.1186/1743–7075–8-54.
• 14 Klement RJ, Champ CE, Kämmerer U. et al. Impact of ketogenic diet intervention during radiotherapy on body composition: III–final results of the KETOCOMP study for breast cancer patients. Breast Cancer Res 2020; 22: 94 DOI: 10.1186/s13058–020–01331–5.
• 15 Raffaghello L, Lee C, Safdie FM. et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci USA 2008; 105: 8215-8220 DOI: 10.1073/pnas.0708100105.
• 16 DeGroot S, Lugtenberg RT, Cohen D. et al. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nat Commun 2020; 11: 3083 DOI: 10.1038/s41467–020–16138–3.
• 17 Alkhayat A, Arao K, Minami T. et al. Ketoacidosis associated with ketogenic diet in a non-diabetic lactating woman. BMJ Case Rep 2020; 13: e234046 DOI: 10.1136/bcr-2019–234046.
• 18 Geijer von L, Ekelund M. Ketoacidosis associated with low-carbohydrate diet in a non-diabetic lactating woman: a case report. J Med Case Rep 2015; 9: 224 DOI: 10.1186/s13256–015–0709–2.
• 19 Fadini GP, Bonora BM, Avogaro A. SGLT2-Inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event reporting System. Diabetologica 2017; 60: 1385-1389 DOI: 10.1007/s00125–017–4301–8.
• 20 Fieger EI, Fadel KM, Modarres AH. et al. Successful reimplementation of a very low carbohydrate ketogenic diet after SGLT2 Inhibitor associated euglyemic diabetic ketoacidosis. AACE Clinical Case Rep 2020; 6: e330-333 DOI: 10.4158/ACCR-2020–0314.
• 21 Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 2016; 7: 135-138 DOI: 10.1111/jdi.12401.